| PDF (4MB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-95529
- DOI to cite this document:
- 10.5283/epub.9552
Abstract
Organ transplantation in presensitized recipients continues to be contraindicated for heart and kidney recipients due to the risk of hyperacute rejection, which has no known treatment at this time. We tested whether donor serum, which contains soluble MHC class I antigen, is able to neutralize the effect of anti-donor antibody in the recipient and prevent hyperacute or accelerated rejection. A ...

Owner only: item control page